Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE